重药控股(000950)官微发布消息称，近日，公司参与投资企业润生药业有限公司（以下简称"润生药 业"）传来喜讯，其申报的核心产品"沙美特罗替卡松吸入粉雾剂"（英文通用名：Fluticasone Propionate and Salmeterol Inhalation Powder USP，药品申请号：ANDA 214464）正式获得美国食品药品监督管理局 （FDA）批准上市，实现国际化里程碑突破。 据悉，这是FDA首次批准中国药企自主研发的吸入粉雾剂（Dry Powder Inhaler，DPI），标志着中国高 端复杂制剂成功叩开国际主流市场大门。该产品以联合用药形式（支气管扩张剂与吸入糖皮质激素）， 用于可逆的气道阻塞性疾病的规律治疗，包括成人和儿童哮喘。润生药业成立于2014年10月，重药控股 下属参股基金公司和亚化医基金在润生药业成立初期投资进入。 此前，重药控股参股子公司重庆药友制药有限责任公司与上海复星医药产业发展有限公司及辉瑞共同签 订许可协议，就口服小分子胰高血糖素样肽-1 受体（GLP-1R）激动剂（包括YP05002）及含有该活性 成分的产品授予辉瑞于许可区域（即全球范围）及领域（即人类、 ...

本报讯1月14日，据重药控股官方微信公众号消息，日前，重药控股参与投资的企业润生药业有限公司 （以下简称"润生药业"）申报的核心产品"沙美特罗替卡松吸入粉雾剂"（英文通用名：Fluticasone Propionate and Salmeterol Inhalation Powder USP，药品申请号：ANDA 214464）正式获得美国食品药品 监督管理局（FDA）批准上市。 此外，值得一提的是，重药控股透露，参股子公司重庆药友制药有限责任公司与上海复星医药产业发展 有限公司及辉瑞共同签订许可协议，就口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂（包括 YP05002）及含有该活性成分的产品授予辉瑞于许可区域（即全球范围）及领域（即人类、动物所有适 应症的治疗、诊断及预防）独家开发、使用、生产及商业化权利。截至目前，药友制药已收到辉瑞支付 的首付款15000万美元。 （文章来源：证券日报） 这是FDA首次批准中国药企自主研发的吸入粉雾剂（Dry Powder Inhaler，DPI），标志着中国高端复杂 制剂成功叩开国际主流市场大门。该产品以联合用药形式（支气管扩张剂与吸入糖皮质激素），用于可 逆 ...

Group 1: Banking and Financial Products - Several private banks, including Suzhou Bank and Huari Bank, have launched large-denomination certificates of deposit with interest rates exceeding 2%, contrasting with the declining rates of state-owned and joint-stock banks [1] - Huari Bank introduced two products with interest rates of 2.15% for 18-month deposits and 2.35% for 2-year deposits, both requiring a minimum subscription of 200,000 yuan [1] - The high-interest products are primarily aimed at customer acquisition and enhancing retail market competitiveness, rather than being a sustainable long-term strategy [1] Group 2: Agriculture and Livestock - The Ministry of Agriculture and Rural Affairs has mandated leading pig farming companies to reduce production capacity, including cutting the number of breeding sows and controlling the weight of pigs at around 120 kg [2] - This marks the first time the National Development and Reform Commission has explicitly required a reduction in the number of breeding sows, indicating a shift in regulatory focus [2] - Financial measures are being implemented alongside production controls, such as restricting credit for expanding pig farming capacity and reducing subsidies that encourage production growth [2] Group 3: Technology and Robotics - The Ministry of Science and Technology is promoting the accelerated application of humanoid robots in sectors like automotive manufacturing, logistics, and power inspection, laying a foundation for a trillion-dollar industry [1] - Significant advancements have been made in key technologies such as multi-modal perception and brain-machine interfaces, which have already benefited patients with paralysis and blindness [1] Group 4: Pharmaceuticals - Chongqing-based Runsheng Pharmaceutical has received approval for its inhalation powder product, fluticasone propionate, marking a significant breakthrough in the high-end inhalation powder market [2] Group 5: IPO and Investment - Zijin Mining International is set to attract major investors like GIC and Millennium Management in its upcoming Hong Kong IPO, which is expected to raise over $3 billion [5] - The IPO is anticipated to be the largest globally since May, with cornerstone investors likely to subscribe to about half of the shares [5] Group 6: Real Estate and Construction - Tian Di Yuan has successfully acquired a state-owned construction land use right in Xi'an for 2.015 billion yuan [10] - Palm Holdings has won a bid for a high-standard farmland construction project in Lankao County, valued at 433 million yuan, which represents 14.12% of its projected annual revenue [9] Group 7: Corporate Financial Issues - Sunac Real Estate has been ordered to execute payments totaling over 920 million yuan due to various legal disputes, contributing to its extensive financial liabilities exceeding 45.4 billion yuan [6] - He Shun Technology has received a warning from the Zhejiang Securities Regulatory Bureau for failing to disclose government subsidies and shareholder contributions in a timely manner [7]